ClinicalTrials.gg

Program

felcorekibart

In GlaxoSmithKline's pipeline, Ultra long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody. Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Nasal Polyps, led by GlaxoSmithKline.

Furthest: phase 3, since Aug 19, 20269 company-led studies, 9 open or runningNext primary completion: Apr 13, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline99 open or runningphase 3since Aug 19, 2026Dec 19, 2024Apr 13, 2027phase 1 · NCT07712393
  • Named in GlaxoSmithKline’s own pipeline as felcorekibart GSK5784283, phase 3, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2024First study: phase 2 study in AsthmaFirst studyNCT06748053 · 307 enrolled · United States, Bulgaria, Canada and more
  2. Jul 14, 2026Phase 1 study in AsthmaNCT07712393 · 24 enrolled · United States
  3. Aug 19, 20266 phase 3 studiesPhase 3 reachedNCT07780669, NCT07780656, NCT07780643 and 3 more
  4. Oct 29, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07915791 · 279 planned

Ahead

  1. Apr 13, 2027Primary completion: phase 1 study in AsthmaNCT07712393
  2. Feb 15, 2029Primary completion: phase 3 study in AsthmaNCT07780643
  3. Mar 6, 2029Primary completion: phase 3 study in Nasal PolypsNCT07782970
  4. Mar 6, 2029Primary completion: phase 3 study in Nasal PolypsNCT07782957

TargetBeta

“Ultra long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody”the company's pipeline, read by Claude · source

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tezepelumabruleAstraZenecaphase 434
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
SHR-1905Jiangsu HengRui Medicinephase 37
TQC2731Sino Biopharmaceuticalphase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07915791Pulmonary Disease, Chronic Obstructive2Not yet recruitingMar 16, 2029279
NCT07782996Asthma · United States, Japan3RecruitingMay 4, 2029370
NCT07782970Nasal Polyps · United States, Japan, Puerto Rico3RecruitingMar 6, 2029218
NCT07782957Nasal Polyps · United States, Australia3RecruitingMar 6, 2029218
NCT07780669Pulmonary Disease, Chronic Obstructive · United States, Japan3RecruitingJul 20, 2029624
NCT07780656Pulmonary Disease, Chronic Obstructive · United States, Argentina3RecruitingJul 20, 2029624
NCT07780643Asthma · United States3RecruitingFeb 15, 2029514
NCT07712393Asthma · United States1Active, not recruitingApr 13, 202724
NCT06748053Asthma · United States, Bulgaria, Canada and more2Active, not recruitingJul 14, 2026307

How it is read

Names in the registry

  • “GSK5784283”, 9 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.